ArticlePloS one2013
Improved mass spectrometry assay for plasma hepcidin: detection and characterization of a novel hepcidin isoform.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 85 citations in OpenAlex.
- Trial
- Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers.Journal of clinical pharmacology · 2017Trial
- The Growth Attainment, Hematological, Iron Status and Inflammatory Profile of Guatemalan Juvenile End-Stage Renal Disease Patients.PloS one · 2015Trial
- Iron overload and morbidities in Chinese with non-transfusion-dependent thalassaemia.British journal of haematology · 2025Article
- Explorative study on the value of hepcidin in predicting iron non-responsiveness in paediatric inflammatory bowel disease.Pediatric research · 2025Article
- Hepcidin analysis in pneumonia: Comparison of immunoassay and LC-MS/MS.Annals of clinical biochemistry · 2023Article
- Hepcidin Status in Cord Blood: Observational Data from a Tertiary Institution in Belgium.Nutrients · 2023Observational
- Menstrual cycle affects iron homeostasis and hepcidin following interval running exercise in endurance-trained women.European journal of applied physiology · 2022Article
- Hepcidin as a Potential Biomarker for the Diagnosis of Anemia.Turkish journal of pharmaceutical sciences · 2022Article
- Clinical interpretation of serum hepcidin-25 in inflammation and renal dysfunction.Journal of mass spectrometry and advances in the clinical lab · 2022Article
- Transferrin Saturation/Hepcidin Ratio DiscriminatesInternational journal of molecular sciences · 2022Article
- Comparative Evaluation of Sucrosomial Iron and Iron Oxide Nanoparticles as Oral Supplements in Iron Deficiency Anemia in Piglets.International journal of molecular sciences · 2021Article
- Hepcidin response to interval running exercise is not affected by oral contraceptive phase in endurance-trained women.Scandinavian journal of medicine & science in sports · 2021Article
- Methodological Approach of the Iron and Muscular Damage: Female Metabolism and Menstrual Cycle during Exercise Project (IronFEMME Study).International journal of environmental research and public health · 2021Observational
- Differentiating iron-loading anemias using a newly developed and analytically validated ELISA for human serum erythroferrone.PloS one · 2021Article
- Changes in Hepcidin Serum Levels Correlate with Clinical Improvement in Idiopathic Restless Legs Syndrome Patients.Journal of clinical medicine · 2020Article
- Menopause Delays the Typical Recovery of Pre-Exercise Hepcidin Levels after High-Intensity Interval Running Exercise in Endurance-Trained Women.Nutrients · 2020Article
- Long-term Effect of Split Iron Dextran/Hemoglobin Supplementation on Erythrocyte and Iron Status, Growth Performance, Carcass Parameters, and Meat Quality of Polish Large White and 990 Line Pigs.Biological trace element research · 2020Article
- New diagnostic tools for delineating iron status.Hematology. American Society of Hematology. Education Program · 2019Article
- Unraveling Hepcidin Plasma Protein Binding: Evidence from Peritoneal Equilibration Testing.Pharmaceuticals (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mass spectrometry (MS)-based assays for the quantification of the iron regulatory hormone hepcidin are pivotal to discriminate between the bioactive 25-amino acid form that can effectively block the sole iron transporter ferroportin and other naturally occurring smaller isoforms without a known role in iron metabolism. Here we describe the design, validation and use of a novel stable hepcidin-25(+40) isotope as internal standard for quantification. Importantly, the relative large mass shift of 40 Da makes this isotope also suitable for easy-to-use medium resolution linear time-of-flight (TOF) platforms. As expected, implementation of hepcidin-25(+40) as internal standard in our weak cation exchange (WCX) TOF MS method yielded very low inter/intra run coefficients of variation. Surprisingly, however, in samples from kidney disease patients, we detected a novel peak (m/z 2673.9) with low intensity that could be identified as hepcidin-24 and had previously remained unnoticed due to peak interference with the formerly used internal standard. Using a cell-based bioassay it was shown that synthetic hepcidin-24 was, like the -22 and -20 isoforms, a significantly less potent inducer of ferroportin degradation than hepcidin-25. During prolonged storage of plasma at room temperature, we observed that a decrease in plasma hepcidin-25 was paralleled by an increase in the levels of the hepcidin-24, -22 and -20 isoforms. This provides first evidence that all determinants for the conversion of hepcidin-25 to smaller inactive isoforms are present in the circulation, which may contribute to the functional suppression of hepcidin-25, that is significantly elevated in patients with renal impairment. The present update of our hepcidin TOF MS assay together with improved insights in the source and preparation of the internal standard, and sample stability will further improve our understanding of circulating hepcidin and pave the way towards further optimization and standardization of plasma hepcidin assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.